PDCD1 and nonpapillary renal cell carcinoma: Similarly, avelumab and atezolizumab follow the same strategy of disrupting the interplay between PD-L1 and PD-1, although further research is still in progress to fully ascertain their effectiveness in treating ccRCC [75].